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Abstract 
 
All antidepressant classes are associated with a withdrawal syndrome. SSRI withdrawal 
syndrome occurs often and can be severe, and may compel patients to re-commence their 
medication. Although the withdrawal syndrome can be differentiated from recurrence of 
the underlying disorder, it may also be mistaken for recurrence, leading to long-term 
unnecessary medication. Authorities currently recommend short tapers, of between two to 
four weeks, down to therapeutic minimum, or half minimum doses before complete 
cessation. Studies have demonstrated that these tapers show minimal benefit over abrupt 
discontinuation, and are often not tolerated by patients. Tapers over months and down to 
doses significantly lower than minimum therapeutic doses have shown greater success 
rates. Other medications associated with withdrawal symptoms are tapered to reduce their 
biological effect at receptors by fixed amounts in order to minimise withdrawal effects. 
These are exponential tapering programmes which reduce to very small doses.  We 
examined the PET imaging data of serotonin transporter occupancy by SSRIs to demonstrate 
that hyperbolically reducing doses of SSRI will reduce their effect on serotonin transporter 
inhibition in a linear manner. We therefore suggest that SSRIs are tapered hyperbolically 
and slowly to doses much lower than therapeutic minimums, in line with tapering regimes 
for other medications associated with withdrawal symptoms. Withdrawal symptoms will 
then be minimised.  
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SSRI withdrawal (‘discontinuation’) syndrome 
 
Many medications are associated with a withdrawal syndrome, most commonly those that 
act on the cardiovascular and central nervous system 1. All major classes of antidepressants 
– MAOIs, TCAs, SSRIs, and SNRIs – are associated with withdrawal symptoms 2,3. The term 
‘discontinuation syndrome’ was coined to refer to this syndrome in antidepressants 4. The 
SSRI discontinuation syndrome, as outlined in DSM-V, and captured in the Discontinuation-
Emergent Signs and Symptoms (DESS) checklist 5 is composed of a wide variety of somatic 
and psychological symptoms (Figure 1). 
 
SSRI withdrawal symptoms can in part resemble the symptoms of anxiety or depression for 
which the medication was originally given 6. However, the withdrawal syndrome can be 
distinguished from a relapse or recurrence of the underlying disorder by its quickness of 
onset (days rather than weeks)3,7,8, rapid response to re-introduction of the antidepressant 
(generally within hours, certainly within days) 3,7,9, and the presence of somatic and 
psychological symptoms quite distinct from the original illness (including, dizziness, nausea, 
and ‘shock-like’ sensations) 7,10. The withdrawal syndrome can be misdiagnosed as 
depressive recurrence, leading to prolonged treatment for patients who may not require it 
11–13, but it is not clear how often this occurs 14. 
 
SSRI withdrawal symptoms occur in many patients, with reported incidence rates varying 
from 42-100% for paroxetine 5,15–18, to 9-77% for fluoxetine 5,15,17,18, and median rates of 
53.6% for SSRIs across 14 studies that examined antidepressant withdrawal 13. The 
incidence and severity appears to be influenced by half-life and receptor affinities, duration 
and dose of usage, as well as method of tapering, and individual patient characteristics 3,9. A 
recent systematic review identified five studies that evaluated the severity of withdrawal 
effects and reported that nearly half of participants who had experienced withdrawal 
effects choosing the most extreme option in the scale offered to them to describe the 
severity of those effects 13. The discontinuation period (14 days after cessation) is also 
associated with a 60% increase in suicide attempts compared with previous users of 
antidepressants (the increased risk therefore attributed to the process of withdrawal and 
not to being untreated) 19. 
 
The syndrome can last for significantly longer than the one to two week period 13, previously 
suggested 4. In one study, the syndrome lasted for at least twelve weeks in 25% of patients 
18, and in another for at least six weeks in 40% of people 20. A third study reported that 
86.7% responded that the syndrome had lasted at least two months, 58.6% at least one 
year, and 16.2% for more than three years 21. Case reports identify symptoms enduring for a 
year or longer 22,23.  
 
The increasingly long-term use of SSRIs - with nearly half of patients in the UK taking 
antidepressants for more than two years 24,25 - arises in part because patients are unwilling 
to stop due to the aversive nature of the withdrawal syndrome 24,26, and a lack of 
information on how to mitigate the syndrome 24,26. Doctors feel that there is not enough 
guidance on how to proceed with discontinuation 24.  
 
Tapering SSRIs 
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Current guidelines suggest short tapers to avoid withdrawal symptoms. NICE 27, the BAP 12, 
MIMS online 28, and UpToDate 29, suggest tapering periods of between two and four weeks, 
with linear reductions of dose down to minimum therapeutic doses, or half that, before 
complete cessation. These guides suggest that fluoxetine does not require tapering 29, or 
that, in high dose, it may be reduced over two weeks 28. Drug manufacturer advice was 
found to be similarly ‘vague and non-specific’ according to recent systematic review 30.  
 
Randomised studies show that tapering for up to 14 days either demonstrated no 16 or 
minimal 31 improvement in withdrawal symptom severity over abrupt discontinuation 32. It 
has generally been concluded from these studies that longer tapering regimes are required 
3,33. Indeed, studies involving longer tapering periods, of months duration, 34–36 have 
demonstrated better outcomes (Table 1). Reduction of paroxetine by 10mg every 2 weeks, 
lowered withdrawal incidence from 34% to 4.6%, when compared with abrupt 
discontinuation in one study 34. When patients who experienced withdrawal in this study 
were recommenced on medication and then tapered at 5mg every 2-4 weeks, withdrawal 
was successfully avoided 34. In another study patients who withdrew from SSRIs over up to 
four months had 5.1 DESS events, compared with 11.7 for patients who abruptly 
discontinued 35.  
 
In another study with paroxetine, patients who withdrew, over an average duration of 38.6 
weeks (range two to 197), titrated to the individual, had a 6% incidence withdrawal 
syndrome, compared with 78% for abrupt discontinuation 36 (Table 1). Tapering strips for 
antidepressants, which reduce medication to small fractions of minimum therapeutic dose 
(for example, 0.5mg for paroxetine and citalopram), have shown favourable outcomes: 
allowing 71% of 1194 patients, 97% of whom had experienced withdrawal previously to 
discontinue their medication over a median of 2 months 14. Several case studies also 
support the improved efficacy of slower tapering 37–39. In one instructive case, several 
months of tapering, down to an average dose of 6.25mg of sertraline per day was required 
to avoid withdrawal symptoms in one man, whose withdrawal-induced orthostatic 
hypotension allowed objective measurement 37.  These findings have led to one 
recommendation to reduce paroxetine by 1% of the original dose every three days 40.   
 
Two recent large studies confirm that shorter tapering regimes, as currently advised, are not 
effective. One study found that tapering over 4 weeks was not feasible, with most (60%) 
patients tapering their medications over 4 months 41. Another study, employing largely 
linear reductions, with final dosages equal to minimum therapeutic doses (or half that 
value) found that only 37% of patients were able to discontinue their medication 42. 
Furthermore, a large study involving 400 patients showed a significantly lower risk of 
relapse if antidepressants were tapered gradually (greater than 14 days), rather than rapidly 
(1-7 days) 43.  
 
Neurobiology of withdrawal and its management 
 
Current approaches to mitigate withdrawal symptoms from SSRIs derive from the rationale 
that tapering SSRIs will extend the period of time over which biological systems are able to 
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adapt to reductions in available ligand, thus reducing the intensity of withdrawal 
symptoms3,12,33,44.  
 
Receptors that are activated by a medication may be down-regulated, or exhibit reduced 
sensitivity 45. Abrupt removal of medication disturbs the homeostatic equilibrium, creating a 
circumstance of reduced stimulation, experienced as withdrawal symptoms, often opposite 
in nature to the original effect of the drug 45. For example, the withdrawal syndrome from 
TCAs which show strong anticholinergic actions are typified by cholinergic effects 46. 
Adaptation to medication is more likely in the case of long term and high-dose use 47,48. 
Medications with shorter half-lives produce withdrawal symptoms with greater incidence, 
greater severity and quicker onset than medications with longer half-lives, probably because 
their withdrawal is associated with more rapid decreases in amount of available ligand 
47,49,50. Withdrawal symptoms can usually be extinguished by re-introduction of the 
discontinued agent, returning the system to homeostatic equilibrium 45. 
 
The principal approach to mitigate withdrawal symptoms is to reduce the rate at which the 
equilibrium is disturbed, allowing time for adaptation of the system to lowered levels of 
ligand, thus limiting withdrawal symptoms to tolerable severity 47. This is achieved either by 
substitution of a longer acting medication before tapering, or slow tapering (of a drug with a 
short half-life) 47,50. 
 
Notably, decreasing medication by constant amounts (linear tapering) tends to cause 
increasingly severe side effects 47,50,51. This phenomenon is probably a consequence of the 
hyperbolic dose-response relationship between a drug and receptor, following the law of 
mass action 52, as typified by the effect of diazepam on its target receptor, GABA-A (Figure 
2a). Consequently, tapering regimes for benzodiazepines advise increasingly small decreases 
in dosage as dosages approach zero 47,50,51, captured epigrammatically as “stop slow as you 
go low” 1.  
 
Withdrawal regimes for benzodiazepines recommend dosage reductions that are 
proportional to the current dose (most commonly suggesting 10% reductions), yielding 
exponentially decreasing regimes, as opposed to linear reductions 47,51,53 (Figure 2b). These 
exponentially decreasing regimes produce approximately linear reductions of effect at the 
target receptor. Reductions are usually made to doses well beneath minimum therapeutic 
doses (that may appear miniscule) before complete cessation. This is done in order to avoid 
a step down in action at the target receptor that is significantly greater than the size of 
steps previously tolerated. For example, the final dose of diazepam recommended by 
tapering regimes is 1mg 47 (equivalent to 2% GABA occupancy 54).  
 
On the premise that withdrawal symptoms abate because of homeostatic adaptations to 
reduced medication levels, a pause is recommended in between dose reductions 47,50,51. 
However, the exact timing of these adaptations is not fully understood and, therefore, most 
guidelines for withdrawal have been developed based on clinical experience; a consensus 
suggests waiting 1-4 weeks in between dose reductions, to allow withdrawal symptoms to 
resolve 47,50. Most guidelines recommend individualisation of this process, given variation in 
adaptation to change in drug levels, and consequent severity and duration of withdrawal 
symptoms 47,50.  
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Pharmacological characteristics of SSRI withdrawal 
 
Whether called a withdrawal or discontinuation syndrome, the syndrome that occurs on 
cessation of SSRIs conforms to the same determinants as other withdrawal syndromes, 
outlined above. Withdrawal symptoms are more common when SSRIs are given in higher 
doses 55,56, or for longer periods 55. Medications with shorter half-lives, like paroxetine, 
produce withdrawal symptoms with greater incidence 5,15–18, quicker onset 5,15–18, and 
greater severity 5,15–18 than medications with longer half-lives, like fluoxetine 5,15,17,18. 
Paroxetine produces withdrawal symptoms within two days 57, whereas fluoxetine’s can be 
delayed by two 9 to six weeks 20.  
 
As with withdrawal from other medications, the appearance of these withdrawal effects 
correlate with percentage reductions in plasma concentration 57. Higher SSRI plasma levels 
before cessation 58 and just after cessation 59 predict increased withdrawal symptoms. Re-
introduction of the discontinued antidepressant generally resolves symptoms within 24 
hours 3. Following the approach to diminishing the withdrawal symptoms from other 
agents, both tapering of SSRIs 9,12 and substitution of the longest acting SSRI, fluoxetine, 3,12 
have been trialled. Individual factors, including genetics 36, have also been thought to play a 
role in determining withdrawal effects.  
 
Neurobiology of SSRI withdrawal 
 
SSRIs are thought to produce their effect through an “initiating” step of inhibition of the 
serotonin transporter (SERT), leading to an increase in synaptic levels of serotonin, thereby 
transducing increased responses at serotonergic receptors 60,61. Serotonergic neurons also 
modulate other neurotransmitter systems including noradrenaline, dopamine and GABA 49. 
Effects on neurogenesis, inflammation, and the HPA axis, downstream of serotonergic 
actions, are also hypothesised in their antidepressant effects 60,62,63. Although the details 
remain to be elucidated, SSRI withdrawal has been attributed to a relative deficiency of 
serotonin in the context of widespread adaptation of serotonergic receptors 9,49,64. The 
association of withdrawal symptoms from paroxetine and the C(-1019)G polymorphism of 
the serotonin 1A receptor (5-HT1A) gene 36, a receptor widely implicated in antidepressant 
action 60, supports this notion. A role is also postulated for the reversal of effect on 
neurotransmitters, including noradrenaline, glutamate and GABA, amongst other targets 
that are indirectly affected by SSRIs 9,49,64.  
 
Serotonin’s role in coordinating sensory and autonomic function with motor activity has 
been implicated in the SSRI withdrawal syndrome 44. Reduced stimulation of raphe 5-HT1A 
receptors, known to be involved in motion sickness 49 is thought to be related to the 
dizziness, vertigo, nausea and lethargy of the withdrawal syndrome 49; dysregulation of 
somatosensory functions may result in paraesthesia, while movement disorders (for 
example, dystonia, sometimes experienced) may be due to altered dopaminergic function 
49. 
 
Pharmacological principles to taper SSRIs 
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Given the characteristics of the SSRI withdrawal syndrome, the rationale for tapering to 
reduce withdrawal symptoms is clear. If plasma (and, therefore, tissue) levels of an SSRI 
drop rapidly, the mismatch between the adapted system and the levels of available ligand 
will be large and so too the consequent severity of the withdrawal symptoms. Slower 
tapering of dose or substitution of an SSRI with a longer half-life, such as fluoxetine, will 
produce more gradual reductions in plasma levels. Akin to other withdrawal syndromes 47, 
neuro-adaptation to lowered levels of available serotonin is likely responsible for resolution 
of withdrawal symptoms following cessation of an SSRI 33,44. Slower tapering will provide 
more time for these neuroadaptations and are likely to diminish withdrawal severity 33,44,47. 
 
As with other withdrawal syndromes, a rational tapering regime for SSRIs will entail step-
wise reductions of their action at their principal receptor target, SERT 60. PET studies, 
utilising radio-ligand bound to SERT, have demonstrated that the dose-response curve 
between SSRIs and SERT, conforms to the typical hyperbolic relationship arising as a 
consequence of the law of mass action (Figure 3). The line of best fit drawn, corresponds to 
a Michaelis-Menten equation 65, applied to such dose-response curves, allows derivation of 
values for the percentage inhibition of SERT, for different dosages of citalopram (see Figure 
3 and Table 2) 61. Notably, SERT inhibition drops off sharply for doses beneath the minimum 
therapeutic dose for SSRIs (Table 2).  
 
It is therefore likely that tapering regimes employing linear dose reductions will cause 
increasingly severe withdrawal reactions, as reductions in SERT inhibition become 
increasingly large (Figure 4a). For example, reductions of 5mg citalopram increments from 
20mg (Figure 4a), will produce hyperbolically increasing-sized decreases to SERT inhibition: 
3% (20mg to 15mg), 6% (15mg to 10mg), 13% (10mg to 5mg) and 58% (5mg to 0mg). 
Indeed, even reductions from 2·5 mg (a quarter of the smallest available tablet) to 0mg will 
produce a reduction in SERT inhibition of 42·9%, and reduction from 1·25mg (an eighth of a 
tablet) to 0mg will produce a 28% reduction (larger than the change from 40mg to 5mg 
(27·3%)), perhaps accounting for the lack of success of previous tapering regimes 41,42, and 
particularly for the difficulties with withdrawal symptoms experienced by people towards 
the end of their taper at low doses 14,37. 
 
In order to produce a linear reduction of pharmacological effect, a hyperbolically decreasing 
pattern of dosage reduction is required (Figure 4b). Rather than decreasing the dose by 
fixed amounts, the dose should be decreased according to fixed intervals of biological 
effect, for example, 10% reductions of SERT occupancy (20% reductions shown in Figure 4b). 
The regime of reduction ensuring approximately 10% SERT occupancy differences between 
each step for citalopram can be seen in Table 2: 20mg, 9·1mg, 5·4mg, 3·4mg, 2·3mg, 1·5mg, 
0·8mg, 0·37mg, 0mg. Appendices show further SSRI examples. These regimes allow 
pharmacologically-informed application of the withdrawing principles outlined above (“stop 
slow as you go low”) 1,51. This regime predicts final doses for tapering close to those 
employed in successful trials involving tapering strips14, and successfully utilised in case 
studies involving difficult withdrawal syndromes 37. 
 
Limitations 
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There are potential limitations to interpretation of the dose-response curve of the PET study 
presented 61. The number of participants in each study is relatively small, perhaps limiting its 
ability to capture individual variation. However, the shape of the dose-response curve (i.e. 
hyperbolic) should be the same for each individual, suggesting hyperbolic dose reduction 
regimes should be universally applicable.  
 
There may also be targets of action of SSRIs in addition to the inhibition of SERT and the 
effect on the serotonergic system, including neurotrophic, anti-inflammatory, and 
neuroendocrine effects 62,63. However, importantly, these myriad effects are thought to be 
downstream of effects on SERT and consequent to changes to the serotonergic system 
60,62,63, indicating that SERT occupancy is likely to be a key indicator of biological response to 
SSRIs. 
 
It is difficult to determine whether SERT inhibition will linearly correspond to withdrawal 
effects. SERT binding is related to the antidepressant effects of SSRIs: the ratio of SERT 
binding between terminal regions and the median raphe nucleus has been shown to predict 
treatment response to SSRIs 66. It is theoretically possible that a minimum threshold of SERT 
inhibition is required before clinical effect is seen, with levels lower than this having minimal 
effects 61; this may correspond to withdrawal effects as well. However, withdrawal effect 
from other medications do not observe threshold effects 47,50, and withdrawal effects have 
been observed at many doses during tapering of SSRIs9,36, suggesting withdrawal is likely to 
be continuous entity. Furthermore, a hyperbolic relationship exists between dose of SSRI 
and reduction of depressed mood, as demonstrated in a mega-analysis 67; a hyperbolic 
relationship has also been demonstrated between dose of SSRI and risk of withdrawal 
symptoms 55. These findings suggest that the hyperbolic relationship between dose and 
SERT inhibition may also be extended to withdrawal effects, suggesting that SERT inhibition 
may be approximately linearly related to withdrawal effects.  
 
Another potential limitation is that SERT occupancy was measured in the striatum in this 
study 61, which may not have direct relevance to antidepressant actions. However, this and 
a subsequent PET study 68 demonstrated that SSRIs cause comparable SERT inhibition in 
brain regions relevant to SSRI action (subgenual cingulate, amygdala and raphe nuclei), with 
a similar hyperbolic relationship between dose of SSRI and SERT occupancy at all regions 
examined 68. Overall, it seems reasonable to conclude that SSRIs, like most pharmacological 
agents, have a hyperbolic relationship to biological effects, and that this may have utility in 
generating rational discontinuation regimes.  
 
Practical application of these principles 
 
There is likely to be individual differences in each person’s experience of SSRI withdrawal 
effects 3. We suggest that an individualised rate for withdrawal could be established by an 
initial trial reduction of SSRI dosage equivalent to a reduction of 10% SERT occupancy (or 5% 
if being cautious), with subsequent monitoring of the severity and duration of withdrawal 
symptoms. If the patient returned to baseline, on DESS scores, after one month, then a rate 
equivalent to 10% reduction of SERT occupancy per month could be prescribed. This process 
should be subject to ongoing monitoring, with the rate titrated to toleration by the patient.   
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The medication should be tapered to a final dose such that a drop to zero is equal to (or less 
than) the size of reduction previously tolerated by the patient. Going by ‘the rule of thumb’, 
this may be when the dose is equivalent to approximately 10% SERT occupancy. Notably, 
this will be a tiny dose of medication – for example, 0.37mg for citalopram. Interestingly, 
studies have reported tapering regimes that have only been successful when they taper to 
similar dosages of SSRIs 14,37. The use of liquid formulations of SSRIs may be necessary to 
achieve these small dosages.   
 
It is difficult to establish the optimal time interval to observe in between dose reductions. 
In the absence of studies evaluating the rate at which neuro-adaptation can occur, several 
aspects can guide us. Pharmacokinetic properties, for all antidepressants, except fluoxetine, 
predict that they will achieve steady state within 5-14 days after dosage reduction (Table 3) 
69. As outlined above, discontinuation symptoms have been detected in patients for varying 
periods of time, from a number of days, to weeks and months, and, in some cases, for more 
than a year 9,22,23,70–72. These records have generally been derived from patients who 
abruptly cease their medication; it may be possible that in more cautious reductions 
discontinuation symptoms are likely to be shorter. The clinical effects of SSRIs may be 
delayed by weeks following their commencement 60 67, whereas side effects arise in days 73. 
It is unclear whether withdrawal symptoms are likely to follow the temporal pattern of 
antidepressant effects, or side effects. Overall, it may be prudent to allow 4 weeks after a 
reduction in SSRI to observe for delayed side effects. This would also allow for observation 
of recurrence of underlying symptoms as a result of the decrease in SSRI dose. However, the 
best guide may be the interval required for DESS symptoms to return to baseline after a test 
reduction for an individual.  
 
Other determinants of withdrawal symptoms from SSRIs 
 
There are likely to be other drug and patient characteristics that affect the severity of 
withdrawal syndromes from SSRIs. Paroxetine and fluoxetine are both metabolised by 
cytochrome P450 2D6 and inhibit their own metabolism, resulting in non-linear kinetics 74. 
This predicts disproportionate declines in plasma concentrations during drug withdrawal. 
While this effect may not be clinically significant for fluoxetine because of its long half-life, it 
is likely to be significant for paroxetine 49. Paroxetine may produce a more severe 
withdrawal syndrome than other SSRIs because it has pronounced muscarinic antagonist 
effects and moderate norepinephrine transporter inhibiting effects 49,64. It is also likely that 
patient factors such as cytochrome p450 iso-enzyme status, SERT sensitivity to inhibition 
and psychological factors may contribute to risk of withdrawal symptoms. Further 
understanding of these factors, and plasma level testing may be instructive in designing 
personalised tapering regimes.  
 
Some practical consequences of these principles 
 
The model proposed also resolves a quandary often raised by patients and treating 
physicians: whether to ‘micro-taper’ or ‘mini-taper’. ‘Micro-tapering’ involves miniscule 
decrements in SSRI medication every day or week. ‘Mini-tapering’ involves step-wise larger 
decrements, with longer intervals in between decrements (generally, weeks). ‘Mini-
tapering’ appears more sensible than ‘micro-tapering’ (although both are linear methods). 
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Withdrawal symptoms are reported to last for several weeks (or longer) after medication 
discontinuation in a significant proportion of patients 9,13. Given this pattern, ‘micro-
tapering’ presents the possibility of cumulative withdrawal effects superimposing upon one 
another. This would make it difficult to establish which reduction (or set of reductions) were 
responsible for symptoms experienced. It therefore seems prudent to decrease the dose of 
medication, allow a significant period of time to elapse while withdrawal effects resolve, 
before commencing the next decrement.  
 
Fluoxetine 
 
Substitution of short acting SSRIs with fluoxetine has been suggested as a way to avoid 
intolerable withdrawal symptoms 3,75. It has been routinely identified to cause less severe 
withdrawal effects than other SSRIs, which has been attributed to its longer half-life 3,30,75. 
Fluoxetine should take 35-75 days to reach steady state 49, a fact that is likely responsible 
for observations that its withdrawal symptoms can arise weeks after cessation 9,20. 
Therefore, it would be prudent to wait three months (35-75 days plus four weeks), to 
observe for late arising withdrawal symptoms. Given fluoxetine’s ‘in-built’ tapering it may 
be reasonable to reduce doses equivalent to approximately 30% SERT occupancy in each 
iteration, titrated as tolerated by the individual.  
 
We should be wary of the idea that fluoxetine is ‘self-tapering’ and can therefore be 
abruptly ceased, or ceased rapidly, as guidelines suggest 30,76. Although its pharmacokinetic 
profile predicts gradual plasma level decline, a short reduction (for example, two weeks 28), 
may still represent a rapid withdrawal schedule - more rapid than the 10% of biological 
effect per month ‘rule of thumb’.  
 
Future directions for research 
 
This paper offers a pharmacologically-informed guide to withdraw from SSRIs. Its validity 
should be confirmed by randomised controlled trials. Withdrawal nomograms aggregating 
variation in responses to withdrawal may help guide taper rates (Figure 5). Risk 
determinants, for example, plasma SSRI level, cytochrome p450 iso-enzyme status, PET 
measurement of SERT occupancy, and other genetic, metabolic and psychological aspects 
could be incorporated into this nomogram, as they are clarified. Pharmacological and non-
pharmacological means to improve the tolerability of SSRI withdrawal also warrant research 
41,42. 
 
We suggest that in the absence of more robust evidence for guiding tapering (especially 
where current guidelines advise to ‘taper gradually’, without concrete instruction) that this 
regime should be adopted into clinical practice, given little disadvantage to recommending 
slower tapers30 . As a minimum, it should be recognised that tapering periods of 2-4 weeks 
are likely inadequate for reducing withdrawal symptoms for many, with longer periods of 
tapering, to lower levels of medication, more likely to be effective. An update of formal 
guidelines is urgently required.  
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